Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALRN 6924

Next Previous
Search
Drug Profile

ALRN 6924

Alternative Names: ALRN-6924

Latest Information Update: 21 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Dana-Farber Cancer Institute; Rein Therapeutics
  • Class Antineoplastics; Immunotherapies; Peptides
  • Mechanism of Action Proto-oncogene protein c-mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Chemotherapy-induced damage; Haematological malignancies; Myelodysplastic syndromes; Radiation injuries; Solid tumours

Most Recent Events

  • 10 Jan 2025 Aileron Therapeutics is now called Rein Therapeutics
  • 17 Jul 2023 Aileron Therapeutics completes a phase I trial in Haematological malignancies and Solid tumours (In infants, In children, In adults, In adolescents, Second-line therapy or greater, Monotherapy, Combination therapy) in USA (IV) (NCT03654716)
  • 23 Feb 2023 Discontinued - Phase-I for Breast cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top